Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Senate Health & Welfare hears testimony on H 266 as hospitals warn 340B reporting would be burdensome
Summary
Hospital and pharmacy representatives told the Senate Health & Welfare Committee that proposed reporting for H 266 — a 340B prescription drug pricing bill — would be difficult to produce, may miss drugs bundled in payments, and mirror data-quality challenges reported in other states.
At a Senate Health & Welfare Committee hearing, witnesses raised concerns that H 266, a bill addressing 340B prescription drug pricing, would impose heavy reporting burdens on hospitals and clinics and would not reliably capture drugs paid through bundled payments.
The 340B program allows certain health centers and hospitals to purchase outpatient drugs at discounted prices. Testimony at the committee hearing focused on whether facilities can produce the payer-level, drug-by-drug payment data the bill seeks and whether that information would be accurate or actionable.
Dawn, identified in testimony as a 340B coordinator at Hartford Medical Center, told the committee that hospitals often cannot itemize drug payments because many payers reimburse services through bundled rates such as inpatient diagnosis-related groups or bundled outpatient procedures. “We can tell you that. But what we get paid for is we…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
